MAKScientific LLC
Business Identifier: NO Business Identifier is currently available for this company.
Public Profile:
MAKScientific, LLC, was founded on the basis of research conducted by a leader in the field of cannabinoids. Our mission is the discovery, development and commercialization of novel therapeutics in the areas of neuropathic, inflammatory and somatic pain, obesity, neuroprotection, and addiction and glaucoma. MAKScientific is a leader in endocannabinoid research with the ability to address major unmet medical needs for selected diseases with clear competitive advantage over present therapies. The Company holds a proprietary understanding of the endocannabinoid biochemical pathways and has validated therapeutic targets. The Company’s proficiency in medicinal chemistry, and molecular biology is dedicated to the human cannabinoid system including the CB1 and CB2 receptors, as well as enzymes and transporters that modulate the endocannabinoid system. The firm's goal is the development of potent and selective cannabinergic compounds (agonists and antagonists) for use as novel medications. The Company has substantial drug development assets that include (i) a large library of over 5,000 potent and highly selective cannabinergic compounds that can potentially lead to the development of novel medications, (ii) validated targets for therapeutic drug development and (iii) a proprietary understanding of the endocannabinoid pathways

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity, Phase
Novel Azetidine Cb1 Antagonists
Novel Cb1 Receptor Antagonist: Phase II-271077424
CB1 Receptor Antagonists in Drug Abuse